Home > Boards > US OTC > Biotechs > Oxford BioMedica PLC (OXBDF)

Q1 Kymriah (USD 45 million) strong demand continued

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
marcusl2 Member Profile
 
Followed By 2
Posts 427
Boards Moderated 0
Alias Born 01/14/14
160x600 placeholder
marcusl2   Wednesday, 04/24/19 06:00:04 AM
Re: None
Post # of 750 
Q1 Kymriah (USD 45 million) strong demand continued and sales increased driven by new treatment sites in the EU, additional progress with reimbursement, coverage for at least one indication in 14 countries, increased manuf capacity and widened commercial spec in the EU.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist